Metolazone As Early Add On Therapy For Acute Decompensated Heart Failure (MELT-HF)--A Single Center Pilot Study.
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 147 participants.
Also called NCT02620384
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 147 participants
- Sponsor
- Aultman Health Foundation
- Registry
-
NCT02620384
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Terminated
Technical summary
Registry record NCT02620384. Randomized; triple masking; primary purpose treatment. Start 2015-10-01 (actual); primary completion 2017-11-29 (actual). Results posted on 2019-02-15.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Metolazone As Early Add On Therapy For Acute Decompensated Heart Failure (MELT-HF)--A Single Center Pilot Study.
- Acronym
- MELT-HF
- Condition
- Acute Decompensated Heart Failure
- Intervention (Drug)
- Experimental: Placebo
- Intervention (Drug)
- Experimental: Metolazone
- Lead sponsor
- Aultman Health Foundation
Record details
- Record id
cardio:ct-nct02620384- Content hash
6660b929811ec97811c58922ef85ed24db39220c8f7680d4571be01056b749bb